Nippon Shinyaku Co Ltd bought $15M of CAPR
owner at CAPRICOR THERAPEUTICS, INC.. 2,798,507 shares at an average of $5.36, traded Sep 20, 2024, filed Sep 24, 2024.
Score components
- +12Role10% owner
- +25Trade size$15.0M at market
- +10Relative to holdingsHoldings up 65%
- +4Price context29% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +133.1%, 3m +54.0%, 6m +48.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000929638-24-003214, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 20, 2024 | POpen-market purchase Common Stock, par value $0.001 per share | +2,798,507 | $5.36 | $15M | 7,090,351 | Sep 24, 2024 |
Related signals
Other insiders at CAPRICOR THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $732k 24,100 shares | -68% | |
| 19Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $732k 24,100 shares | -44% | |
| 0Weak | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $27k 900 shares | -8% | |
| 0Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $27k 900 shares | -3% | |
| 37Weak | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $793k 25,000 shares | -75% | |
| 20Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $793k 25,000 shares | -45% | |
| 28Weak | CAPRICOR THERAPEUTICS, INC. | Karimah Es Sabar director | $241k 7,529 shares | -100% | |
| 44Moderate | CAPRICOR THERAPEUTICS, INC. | Anthony Bergmann CHIEF FINANCIAL OFFICER | $753k 25,000 shares | -75% | |
| 27Weak | CAPRICOR THERAPEUTICS, INC. | Karen Krasney EVP, GENERAL COUNSEL | $753k 25,000 shares | -45% | |
| 40Moderate | CAPRICOR THERAPEUTICS, INC. | Karimah Es Sabar director | $3.5M 115,000 shares | -188% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.